Puma Biotechnology Stock Total Debt
| PBYI Stock | USD 3.45 0.11 3.29% |
Puma Biotechnology fundamentals help investors to digest information that contributes to Puma Biotechnology's financial success or failures. It also enables traders to predict the movement of Puma Stock. The fundamental analysis module provides a way to measure Puma Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Puma Biotechnology stock.
Puma |
Puma Biotechnology Company Total Debt Analysis
Puma Biotechnology's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Puma Biotechnology Total Debt | 52.36 M |
Most of Puma Biotechnology's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Puma Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Puma Biotechnology has a Total Debt of 52.36 M. This is 98.1% lower than that of the Biotechnology sector and 83.88% lower than that of the Health Care industry. The total debt for all United States stocks is 99.02% higher than that of the company.
Puma Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Puma Biotechnology's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Puma Biotechnology could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics of similar companies.Puma Biotechnology is currently under evaluation in total debt category among its peers.
Puma Fundamentals
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 137.82 M | ||||
| Shares Outstanding | 49.61 M | ||||
| Shares Owned By Insiders | 15.35 % | ||||
| Shares Owned By Institutions | 59.27 % | ||||
| Number Of Shares Shorted | 3.07 M | ||||
| Price To Earning | 18.52 X | ||||
| Price To Book | 1.79 X | ||||
| Price To Sales | 0.70 X | ||||
| Revenue | 230.47 M | ||||
| Gross Profit | 166.06 M | ||||
| EBITDA | 48.08 M | ||||
| Net Income | 30.28 M | ||||
| Cash And Equivalents | 77.96 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 52.36 M | ||||
| Debt To Equity | 5.19 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | 1.88 X | ||||
| Cash Flow From Operations | 38.92 M | ||||
| Short Ratio | 8.06 X | ||||
| Earnings Per Share | 0.62 X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 4.33 | ||||
| Number Of Employees | 172 | ||||
| Beta | 1.33 | ||||
| Market Capitalization | 160.74 M | ||||
| Total Asset | 213.33 M | ||||
| Retained Earnings | (1.31 B) | ||||
| Working Capital | 51.55 M | ||||
| Current Asset | 223.55 M | ||||
| Current Liabilities | 32.44 M | ||||
| Net Asset | 213.33 M |
About Puma Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Puma Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Puma Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Puma Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out Puma Biotechnology Piotroski F Score and Puma Biotechnology Altman Z Score analysis. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.